Skip to main
  1. Stocks
  2. Opus Genetics
  3. Forecast
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics is well positioned fundamentally because its BEST1 program has shown positive low-dose data, FDA-aligned microperimetry endpoints, and an over-enrolled 11-patient high-dose Cohort 2 that could validate a larger registrational path, with topline data on track for 1Q27. Its LCA5 Phase III is fully enrolled with dosing expected in 4Q26, while RDH12 IND clearance adds a third near-term clinical catalyst, reinforcing a diversified and increasingly de-risked rare eye disease pipeline. Financially, the company gains incremental support from a $10 million phentolamine milestone, royalties starting in the low teens, cash runway into 2029, and meaningful optionality from potential PRV monetization, with management and analysts highlighting low OpEx and attractive gross-margin economics.

Bears say

Opus Genetics is viewed negatively because its value depends heavily on two lead gene therapy programs that are still exposed to early clinical uncertainty, with OPGx-BEST1 supported only by a small, open-label five-patient Cohort 1 and OPGx-LCA5 not yet dosing after completion of the six-month run-in period. Regulatory risk is material since FDA alignment does not guarantee approval, while small patient populations, subretinal surgery, manufacturing setbacks, and intellectual property challenges could delay or limit commercialization and adoption. Financially, the company remains an unprofitable small-cap with significant cumulative losses, will likely need substantial additional capital despite a runway into 2029, and weaker PRV outcomes or higher development costs could force dilution.

Opus Genetics (IRD) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Opus Genetics (IRD) Analyst Forecast & Price Prediction

Get the latest Opus Genetics (IRD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Opus Genetics (IRD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Buy based on their latest research and market trends.

According to 13 analysts, Opus Genetics (IRD) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Opus Genetics (IRD) Analyst Forecast & Price Prediction

Get the latest Opus Genetics (IRD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Opus Genetics (IRD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IRD stock data and trends